EUVIMEDEUVIMED entdecken
Open Access

Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis

Paula Pernea, Cecile Méni, Julien Rossignol, Hélène Aubert, Sébastien Barbarot, Nathalia Bellon, Anne-Claire Bing-Lecointe, Julie Bonigen, Anne-Claire Bursztejn, Delphine Carré, Alice Phan, Eve Puzenat und 16 weitere

JAMA Dermatology · 01.08.2025 · 161 (8) · 855

DOI: 10.1001/jamadermatol.2025.1488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.08.2025. Verfasst von Paula Pernea und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Reference Center for Rare Skin Disorders in Children, AP-HP, Necker Children's Hospital, Paris Centre University, Paris, F…. Hauptthemen laut MEDLINE: Mastocytosis, Cutaneous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Diffuse cutaneous mastocytosis (DCM) is a rare and severe subtype of pediatric mastocytosis, characterized by extensive skin involvement. Comprehensive studies on the clinical and molecular features of DCM remain limited.

Objective

To describe the clinical, molecular, and treatment-related characteristics and outcomes of a cohort of pediatric patients with a clinical presentation of DCM. Design, Setting, and Participants This retrospective study analyzed pediatric patients with a clinical presentation of DCM from January 1996 to October 2023 at Necker Children’s Hospital in Paris, France. Main Outcome and Measures Data on clinical presentation, laboratory results, and KIT sequencing from skin biopsies and bone marrow, if available, were collected and analyzed. These data were compared with previously published findings from a pediatric cohort with maculopapular cutaneous mastocytosis (MPCM).

Results

The study included 33 pediatric patients, 18 (54.5%) of whom were male, with a clinical presentation of DCM, including 4 with aggressive systemic mastocytosis (ASM) and 29 with DCM. The mean (SD) age at the onset of the first clinically significant signs was 2.2 (2.2) months. A disease-revealing massive bullous eruption was noted in 9 patients (27.2%). Compared to MPCM, patients with a clinical presentation of DCM had a higher mean baseline serum tryptase level (47.5 μg/L [SD, 38.7; range, 5.0-178.0 μg/L] vs 7.4 μg/L [SD, 6.4; range, 1-45.2]; P < .001), a higher prevalence of anaphylaxis (4 [12.1%] vs 5 [2.4%]; P = .02), and a more frequent association with ASM (4 [12.1%] vs 2 [0.9%]; P = .004). KIT codon 816 variants were identified in 4 patients (19.0%), other KIT variants in 14 patients (66.7%), and wild-type KIT in 3 patients (14.3%). All 4 patients with KIT codon 816 variants had ASM. Seven patients (21.2%) received early systemic treatment (imatinib, midostaurin, or sirolimus depending on the type of KIT variants), starting at a mean (SD) age of 80.8 (135.6) months and continuing for a mean (SD) of 4.0 (2.6) years, with generally good tolerance and efficacy. Of the 15 patients without systemic treatment for more than 6 years, 13 (86.6%) exhibited spontaneous regression. Conclusion and Relevance In this cohort study, DCM presentation differs significantly from MPCM, with a higher risk of anaphylaxis and aggressive systemic forms, the latter being consistently associated with the KIT D816V variant. Tyrosine kinase inhibitors and sirolimus were generally effective and well tolerated in this pediatric population, with the choice of treatment depending on the type of KIT variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mastocytosis, CutaneousHumansMaleRetrospective StudiesFemaleChild, PreschoolInfantChildProto-Oncogene Proteins c-kitSkinBiopsyAdolescentFrance

Substanzen

Proto-Oncogene Proteins c-kitKIT protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Reference Center for Rare Skin Disorders in Children, AP-HP, Necker Children's Hospital, Paris Centre University, Paris, France.
  • CEREMAST, Imagine Institute, INSERM U1163, AP-HP, Necker Children's Hospital, Paris Centre University, Paris, France.
  • Department of Hematology, Necker Children's Hospital, AP-HP, Paris Centre University, Paris, France.
  • Department of Dermatology, CHU Nantes, Nantes, France.
  • Department of Dermatology, Centre Hospitalier Annecy Genevois, Metz-Tessy, France.
  • Department of Dermatology, Hôpitaux de Brabois, Vandœuvre-lès-Nancy, France.

Zitieren

APA

Pernea, P., Méni, C., Rossignol, J., Aubert, H., Barbarot, S., Bellon, N., Bing-Lecointe, A. C., Bonigen, J., Bursztejn, A. C., Carré, D., Phan, A., Puzenat, E., Skowron, F., Vabres, P., Welfringer-Morin, A., Drabent, P., Fraitag, S., Garcelon, N., Agopian, J., …, & and the (2025). Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis. JAMA Dermatology, 161(8), 855. https://doi.org/10.1001/jamadermatol.2025.1488

Vancouver

Pernea P, Méni C, Rossignol J, Aubert H, Barbarot S, Bellon N, et al. Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis. JAMA Dermatology. 2025;161(8):855. doi:10.1001/jamadermatol.2025.1488

BibTeX
@article{Pernea2025,
  author = {Pernea, Paula and Méni, Cecile and Rossignol, Julien and Aubert, Hélène and Barbarot, Sébastien and Bellon, Nathalia and Bing-Lecointe, Anne-Claire and Bonigen, Julie and Bursztejn, Anne-Claire and Carré, Delphine and Phan, Alice and Puzenat, Eve and Skowron, François and Vabres, Pierre and Welfringer-Morin, Anne and Drabent, Philippe and Fraitag, Sylvie and Garcelon, Nicolas and Agopian, Julie and Dubreuil, Patrice and Mallet, Stéphanie and Barete, Stéphane and Arock, Michel and Hermine, Olivier and Bodemer, Christine and Polivka, Laura and CEREMAST network, CEREMAST network and and the, and the},
  title = {Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis},
  journal = {JAMA Dermatology},
  year = {2025},
  volume = {161},
  number = {8},
  pages = {855},
  doi = {10.1001/jamadermatol.2025.1488}
}
Kostenlos starten →